ImmunityBio Inc 2025年季度报告

FORM10-Q (Mark One) IMMUNITYBIO,INC. (Exact name of registrant as specified in its charter)_____________________________________ Registrant’s telephone number, including area code: (844)696-5235_____________________________________ Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant (1)has filed all reports required to be filed by Section13 or 15(d) of the Securities Exchange Act of1934 during the preceding 12months (or for such shorter period that the registrant was required to file such reports), and (2)has been subject to suchfiling requirements for the past 90days.YesþNo¨ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule405of RegulationS-T (§232.405 of this chapter) during the preceding 12months (or for such shorter period that the registrant was required to submitsuch files).YesþNo¨ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, oran emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growthcompany” in Rule12b-2 of the Exchange Act. If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with anynew or revised financial accounting standards provided pursuant to Section13(a) of the Exchange Act.¨ The number of shares of the Registrant’s common stock outstanding as of May8,2025 was882,620,409(excluding 163,800shares held by amajority owned subsidiary of ours which are treated as treasury shares for accounting purposes). TABLE OF CONTENTS Defined Terms Unless expressly indicated or the context required otherwise, the terms “ImmunityBio,” “thecompany,” “we,” “us,” and“our” in this Quarterly Report refer to ImmunityBio,Inc., a Delaware corporation, and, where appropriate, its subsidiaries. We havealso used several other terms in this QuarterlyReport, the unaudited condensed consolidated financial statements and accompanyingnotes included herein, most of which are defined below: PART I—FINANCIAL INFORMATION ImmunityBio, Inc. and SubsidiariesCondensed Consolidated Balance Sheets(Unaudited; in thousands, except share and per share amounts) ImmunityBio, Inc. and SubsidiariesCondensed Consolidated Balance Sheets (Continued)(Unaudited; in thousands, except share and per share amounts) ImmunityBio, Inc. and SubsidiariesCondensed Consolidated Statements of Operations(Unaudited; in thousands, except per share amounts) ImmunityBio, Inc. and SubsidiariesCondensed Consolidated Statements of Comprehensive Loss(Unaudited; in thousands) The accompanying notes are an integral part of these condensed consolidated financial statements. ImmunityBio, Inc. and SubsidiariesCondensed Consolidated Statements of Stockholders’ Deficit(Unaudited; in thousands, except share amounts) ImmunityBio, Inc. and SubsidiariesCondensed Consolidated Statements of Stockholders’ Deficit (Continued)(Unaudited; in thousands, except share amounts) ImmunityBio, Inc. and SubsidiariesCondensed Consolidated Statements of Cash Flows(Unaudited; in thousands) ImmunityBio, Inc. and SubsidiariesCondensed Consolidated Statements of Cash Flows (Continued)(Unaudited; in thousands) ImmunityBio, Inc. and SubsidiariesCondensed Consolidated Statements of Cash Flows (Continued)(Unaudited; in thousands) ImmunityBio, Inc. and SubsidiariesNotes to Unaudited Condensed Consolidated Financial Statements 1.Description of Business In these notes to unaudited condensed consolidated financial statements, the terms “ImmunityBio,” “the company,” “we,”“us,” and “our” refer to ImmunityBio, Inc. and its subsidiaries. Our Business ImmunityBio is a vertically-integrated biotechnology company developing next-generation therapies and vaccines that bolsterthe natural immune system to defeat cancers and infectious diseases. The company’s range of immunotherapy and cell therapyplatforms, alone and together, act to drive an immune response with the goal of creating durable and safe protection against disease.Designated an FDA Breakthrough Therapy, ANKTIVA is the first FDA-approved immunotherapy for non-muscle invasive bladdercancer CIS that activates natural killer cells, Tcells, and memory Tcells for a long duration response. The company is applying ourscience and platforms to treating cancers, including the development of potential cancer vaccines, as well as developingimmunotherapies and cell therapies that we believe sharply reduce or eliminate the need for standard high-dose chemotherapy. Theseplatforms and their associated product candidates are designed to be more effective, accessible, and easily administered than currentstandards of care in oncology and infectious diseases. Our platforms and their associated product and product candid